Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers
In order to investigate the potential of nanostructured lipid carriers for efficient and targeted delivery of curcumin, the pharmacokinetic parameters of curcumin-loaded nanostructured lipid carriers (Cur-NLC) were evaluated in rats after a single intraperitoneal dose of Cur-NLC. In addition, the an...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2017-09-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/acph-2017-0021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572691445448704 |
|---|---|
| author | Wang Fengling Chen Jin Dai Wenting He Zhengmin Zhai Dandan Chen Weidong |
| author_facet | Wang Fengling Chen Jin Dai Wenting He Zhengmin Zhai Dandan Chen Weidong |
| author_sort | Wang Fengling |
| collection | DOAJ |
| description | In order to investigate the potential of nanostructured lipid carriers for efficient and targeted delivery of curcumin, the pharmacokinetic parameters of curcumin-loaded nanostructured lipid carriers (Cur-NLC) were evaluated in rats after a single intraperitoneal dose of Cur-NLC. In addition, the anticancer activity of Cur-NLC against human lung adenocarcinoma A549 cells was verified by a cellular uptake study, and a cytotoxicity and apoptosis assay. Bioavailability of Cur-NLC was better than that of native curcumin (p > 0.01), as seen from the area under the plasma concentration-time curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and total plasma clearance (CLz/F). Cur-NLC has a more obvious lung-targeting property in comparison with native curcumin. Cur-NLC showed higher anticancer activity in vitro against A549 cells than native curcumin (IC50 value of 5.66 vs. 9.81 mg L−1, respectively). Meanwhile, Cur-NLC treated A549 cells showed a higher apoptosis rate compared to that of native curcumin. These results indicate that NLC is a promising system for the delivery of curcumin in the treatment of lung adenocarcinoma. |
| format | Article |
| id | doaj-art-7768acb8d18f4bd6861124451df0f943 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2017-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-7768acb8d18f4bd6861124451df0f9432025-02-02T08:32:25ZengSciendoActa Pharmaceutica1846-95582017-09-0167335737110.1515/acph-2017-0021acph-2017-0021Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriersWang Fengling0Chen Jin1Dai Wenting2He Zhengmin3Zhai Dandan4Chen Weidong5Department of Pharmacy, The Second People’s Hospital of Hefei, Hefei230011, Anhui, People’s Republic of ChinaDepartment of Pharmacy, The Second People’s Hospital of Hefei, Hefei230011, Anhui, People’s Republic of ChinaDepartment of Pharmacy, The Second People’s Hospital of Hefei, Hefei230011, Anhui, People’s Republic of ChinaDepartment of Pharmacy, The Second People’s Hospital of Hefei, Hefei230011, Anhui, People’s Republic of ChinaDepartment of Pharmacy, The Second People’s Hospital of Hefei, Hefei230011, Anhui, People’s Republic of ChinaInstitute of Pharmacokinetics, Anhui University of Chinese Medicine, Hefei230012, Anhui, People’s Republic of ChinaIn order to investigate the potential of nanostructured lipid carriers for efficient and targeted delivery of curcumin, the pharmacokinetic parameters of curcumin-loaded nanostructured lipid carriers (Cur-NLC) were evaluated in rats after a single intraperitoneal dose of Cur-NLC. In addition, the anticancer activity of Cur-NLC against human lung adenocarcinoma A549 cells was verified by a cellular uptake study, and a cytotoxicity and apoptosis assay. Bioavailability of Cur-NLC was better than that of native curcumin (p > 0.01), as seen from the area under the plasma concentration-time curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and total plasma clearance (CLz/F). Cur-NLC has a more obvious lung-targeting property in comparison with native curcumin. Cur-NLC showed higher anticancer activity in vitro against A549 cells than native curcumin (IC50 value of 5.66 vs. 9.81 mg L−1, respectively). Meanwhile, Cur-NLC treated A549 cells showed a higher apoptosis rate compared to that of native curcumin. These results indicate that NLC is a promising system for the delivery of curcumin in the treatment of lung adenocarcinoma.https://doi.org/10.1515/acph-2017-0021curcuminnanostructured lipid carrierspharmacokineticanticancer effectslung adenocarcinoma |
| spellingShingle | Wang Fengling Chen Jin Dai Wenting He Zhengmin Zhai Dandan Chen Weidong Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers Acta Pharmaceutica curcumin nanostructured lipid carriers pharmacokinetic anticancer effects lung adenocarcinoma |
| title | Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers |
| title_full | Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers |
| title_fullStr | Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers |
| title_full_unstemmed | Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers |
| title_short | Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers |
| title_sort | pharmacokinetic studies and anticancer activity of curcumin loaded nanostructured lipid carriers |
| topic | curcumin nanostructured lipid carriers pharmacokinetic anticancer effects lung adenocarcinoma |
| url | https://doi.org/10.1515/acph-2017-0021 |
| work_keys_str_mv | AT wangfengling pharmacokineticstudiesandanticanceractivityofcurcuminloadednanostructuredlipidcarriers AT chenjin pharmacokineticstudiesandanticanceractivityofcurcuminloadednanostructuredlipidcarriers AT daiwenting pharmacokineticstudiesandanticanceractivityofcurcuminloadednanostructuredlipidcarriers AT hezhengmin pharmacokineticstudiesandanticanceractivityofcurcuminloadednanostructuredlipidcarriers AT zhaidandan pharmacokineticstudiesandanticanceractivityofcurcuminloadednanostructuredlipidcarriers AT chenweidong pharmacokineticstudiesandanticanceractivityofcurcuminloadednanostructuredlipidcarriers |